PP-239: Coronary Thrombus Aspiration Beyond the “Golden Hours”: Is It a Valid Option? (original) (raw)

Objective: Today, aspirin is the cornerstone of antiplatelet therapy in cardiovascular medicine. However the antiplatelet effect of aspirin is not uniform in all patients. Previously published work has demonstrated aspirin resistance in 0.4% to 83.3% of aspirin-treated patients. The aim of this study was to investigate the frequency of aspirin resistance who were taking 100 mg of aspirin and the effect of aspirin resistance on advers clinical events. Methods: 168 patients (115 males and 53 females, mean age 60.1±8.4 years) with stable coronary artery disease who are using aspirin 100 mg/day were included the study. Modified thromboelastogram was used to determine aspirin responsiveness. Aspirin resistance definitions included <50% arachidonic acid induced whole blood trombosit aggregation inhibition by TEG. The patients were followed for an average 464±264 days. The primary outcome were the cardiovascular death due to myocardial infarction (MI), acute coronary syndrome requiring hospitalization and recurrent interventional treatment.